Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Elritercept by Keros Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval
Elritercept is under clinical development by Keros Therapeutics and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase...
Elritercept by Keros Therapeutics for Anemia: Likelihood of Approval
Elritercept is under clinical development by Keros Therapeutics and currently in Phase II for Anemia. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of Keros Therapeutics's Elritercept?
Elritercept is a fusion protein commercialized by Keros Therapeutics, with a leading Phase II program in Anemia. According to Globaldata,...